role of tranexamic acid in cesarean section
Post on 16-Apr-2017
312 Views
Preview:
TRANSCRIPT
قالوا سبحانك ال علم لنا إال ما علمتنا إنك أنت العليم
الحكيم 32صدق الله العظيم البقرة
بسم الله الرحمن الرحيم
Cesarean section rates have increased to as high as 25 – 30% in many areas of the world, In United States cesarean section rate reached 31.3% , the CS rate is 25.5% in United Kingdom. In 2008 EDHS reported that more than 25% of deliveries were by CS.
The average blood loss during cesarean delivery (1000 mL) is double the amount lost during vaginal delivery (500 mL). The hematocrit falls by 10% and blood transfusion is required in 6% of women undergoing cesarean delivery.
In severe cases , CS may result in major obstetric hemorrhage, hysterectomy, admission to an intensive care unit, or maternal death. Medications, such as oxytocin, misoprostol, prostaglandin F2α, and methyl ergonovine, have been used to control bleeding after CS.
Obstetric hemorrhage remains one of the major determinants of maternal death in both developed and developing countries.
Reducing intrapartum and postpartum bleeding in both cesarean section and vaginal delivery patients is very important to reduce the rates of maternal mortality and morbidity. Tranexamic acid (TXA), a synthetic derivate of the amino acid lysine, is an antifibrinolytic that reversibly inhibits the activation of plasminogen, thus inhibiting fibrinolysis and reducing bleeding.
TXA has been used to reduce blood loss and the need for blood transfusion in cardiac surgery, liver transplantation, and orthopedic surgical procedures. Furthermore, TXA decreases the risk of death in bleeding trauma patients
In gynecology and obstetrics, TXA is most commonly used to treat idiopathic menorrhagia . Bleeding associated with pregnancy (placental abruption, placenta previa) has also been treated with TXA.
Aim of the work was to:
Reach the minimal blood loss during elective cesarean section in order to decrease patients' morbidity by using Tranexamic acid injection before operation time .
The following study was conducted at Zagazig University Hospitals and El Mataria Teaching Hospital.
A non-randomized controlled study was carried out over a period of eight months from December 2014 to July 2015.
220 women attending to labor ward for elective cesarean section- were recruited in our study to be divided into two groups.
Group1 (The study Group) consisted of 110 pregnant females who were subjected to: 1 gm TXA was administered by slow IV inj. 10 min. before skin incision . After delivery of the neonate, 10 units of oxytocin were administered by IV drip.
Group 2 (The control group) consisted of 110 pregnant females who were subjected to:10 ml. normal saline solution were administered by slow IV inj. 10 min. before skin incision .Oxytocin was given as in study group.
Inclusion Criteria:
Pregnant women with singleton living fetus.
Completed 37 weeks gestational age or above.
Exclusion criteria: Severe medical and surgical complications
involving the heart, liver or kidney, brain disease and blood disorders.
Bleeding tendency. Known allergy to tranexamic acid. History of thrombo-embolic disorders. pregnancy complications, such as preeclampsia. Abnormally situated placenta(previously detected
by U/S). Ante-partum hemorrhage. Multiple pregnancies, Fetal macrosomia,
polyhydramnios. Fetal distress.
All patients were subjected to:Informed consent: obtained from the patients.Full History taking: including Full personal history and
medical history of present pregnancy with baseline data of maternal age , Parity & Estimated gestational age.
Clinical observation :Vital signs: HR,RR&BP were checked before cesarean section
and immediately after placental delivery, one and two hours after birth, respectively.
Maternal side effects caused by TXA such as GIT upsets, visual disturbances, itching, symptoms and signs indicating thrombosis.
Need for other surgical measures to stop bleeding.
Operative procedures: All patients underwent elective CS under spinal anaesthesia.
Laboratory Investigations: Complete blood count (CBC) was performed before delivery
and 24 hours after cesarean section .
Estimated blood loss by equation using haematocrit levels .
Estimated blood loss
where EBV (estimated blood volume) in mL=the woman’s weight in kg×85.
Evaluation of the efficacy and safety of TXA in CS:
Efficacy:1. Measuring the quantity of blood loss.2. The incidence of postpartum hemorrhage was observed.
Safety:1. Vital signs monitoring.2. General and local reactions caused by TXA were guarded .
Demographic data in both groups
Characteristics
Control group
Tranexamic acid group
t/X2 P
N % N %
Age <30>30
Mean ±SD
8327
75.524.5
8228
74.525.5
0.024
0.86
27.8±4.98 27.36±5.9 0.605
0.546
Parity Multipara 98 89.1 93 84.50.99 0.3
1PG 12 10.9 17 15.5
Graphic representation of Age distribution
control group Tranexamic acid group
0
10
20
30
40
50
60
70
80
90 83 82
27 28
below 30 yearsmore than 30 years
Graphic representation of Parity distribution
control group Tranexamic acid group0
10
20
30
40
50
60
70
80
90
100
12 17
98 93
PGMultipara
comparison between control and TXA group regard GA and weight of pt. before CS.
Characteristics
Control groupN=110
Tranexamic acid groupN=110
t P
Gestational age (GA) in (wks.)
38.5±0.9 38.53±1.57 -0.210 0.834
Weight (kg.) 75.84±6.04 76.8±5.3 -1.299 0.195
comparison between control and TXA group as regard heart rate(HR) before, during, 1 hour and 2 hours after CS.
CharacteristicsControl group N=110
Tranexamic acid group N=110
t P
HR pre operative (B/min.) 84.12±4.4 84.49±3.5 -0.673 0.501
HR during operation(B/min.) 88.09±11.5 90.87±3.59 -2.407 0.017*
HR 1 hour post operative(B/min.) 83.99±4.3 81.93±3.5 3.824 0.00**
HR 2 hour post operative(B/min.) 85.0±3.7 85.03±8.06 -0.043 0.966
comparison between both groups as regard SBP and DBP before, during, 1 hour and 2 hours after CS. Characteristics
Control group N=110
TXA group N=110
t P
SBP pre operative (mmHg) 113.5±9.3 114.5±6.9 -0.904 0.367
DPB pre operative(mmHg)
74.17±7.5 73.87±6.3 1.731 0.092
SBP during operation(mmHg) 109.72±8.1 108.95±5.8 0.715 0.476
DBP during operation(mmHg) 69.87±9.8 68.54±8.2 1.881 0.071
SBP 1 hour post operative(mmHg)
115.74±8.55 114.77±6.88 0.929 0.354
DBP 1 hour post operative(mmHg)
78.1±8.7 75.95±9.51 2.536 0.01*
SBP 2 hour post operative(mmHg)
109.81±7.61 110.25±4.4 -1.736- 0.091
DBP 2 hour post operative(mmHg)
72.19±7.5 72.22±6.3 -0.039- 0.969
Comparison between both groups with regard RR.
Characteristics
Control group
N=110
Tranexamic acid
group
N=110
t P
RR pre Operative
(Cycle/min.)18.84±3.4 18.82±3.1 -0.954 0.221
RR during Operation
(Cycle/min.)22.2±1.49 21.3±1.3 5.452 0.00**
RR 1hour post
Operative
(Cycle/min.)
18.98±1.3 17.83±0.69 8.046 0.00**
RR 2hour post
Operative
(Cycle/min.)
18.07±1.18 17.17±0.58 7.128 0.00**
comparison between both groups as regard hematocrit difference, blood loss and Hematocrit CS. value pre and post
Characteristics Control groupN=110
Tranexamic acid groupN=110
t P
Hematocrit pre_operative (%) 37.18±1.59 36.88±1.69 1.62 0.110
Hematocrit post _operative (%) 32.63±1.7 33.48±1.72 -2.788 0.006*
Hematocrit difference(%) 4.49±0.78 3.44±0.97 5.311 0.00**
BLOOD LOSS (ml.) 773.79±141.7 647.93±155.0 6.284 0.00**
Comparison of Surgical Outcomes between Groups
Characteristicscontrol Group
(n=110)
Tranexamic Acid
Group (n=110)X2 P
Blood loss >1000 mL (n, %) 9 (8.2%) 2 (1.8%) 4.689 0.03*Blood transfusion (n, %) 2(1.8%) 1(0.9%) 0.3 0.58
Additional uterotonic agent
(n, %)12 (10.9%) 10 (9.09%) 0.164 0.684
Thromboembolic events (n,
%)
1. Deep venous thrombosis
2. Myocardial infarction
3. Stroke
4. Renal failure
5. Pulmonary embolism
-
-
-
-
-
-
-
-
-
-
- -
Graphic representation of the number of women who experienced PPH in both
groups
study groupcontrolgroup no.
TOTAL
2 9
110 110Estimated blood loss >1000mL
no. TOTAL
: We concluded that TXA is effective in reducing the amount of blood loss
during and after CS .
TXA decrease the percentage of patients with blood loss >1000 mL.
Additionally, no increase in the incidence of thromboembolic events was observed. Also, Its use is not associated with increased risk of mild adverse drug reactions like nausea, vomiting or diarrhoea.
Cont.…
Although this study is not the first of its kind on this matter however, it confirms the effectiveness and safety of TXA in reducing bleeding in elective CS.
:We recommend thatTranexamic acid is valuable and significantly
reduces the quantity of blood loss during and after CS but further studies are needed to exclude any short or long term effects on the mother or the fetus.
The limitations of the study include a small sample size. So, we recommend further studies involving larger sample size to realize the incidence of occurrence of side effects caused by TXA .
Cont.…
Further studies should include anemic women and those having a risk for PPH. In these groups, TXA may be more beneficial.
top related